Jason Wingard
Distinguished Scholar on the Future of Work | Senior Advisor, Harvard University | Former Dean, Columbia University | CLO, Goldman Sachs | Author of 4 Books
2020 Nobel Laureate in Physiology or Medicine | Discoverer of Hepatitis C Virus | Senior Scholar, NIH Clinical Center
Harvey Alter's decades of patient research at the NIH led to the discovery of the hepatitis C virus — a breakthrough that eliminated transfusion-transmitted hepatitis from the U.S. blood supply and paved the way for treatments that have since cured millions worldwide. The 2020 Nobel Laureate in Physiology or Medicine brings rare depth, hard-won wisdom, and a celebrated wit to the stage, making the story of one of medicine's greatest quests both compelling and unforgettable.
Want to book Harvey Alter as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
Harvey J. Alter is one of the most consequential medical scientists of the 20th century — a virologist, physician, and 2020 Nobel Laureate in Physiology or Medicine whose decades of patient, methodical research at the National Institutes of Health led to the discovery of the hepatitis C virus and, ultimately, to treatments that have cured millions of people worldwide. Born in New York City in 1935, Alter joined the NIH Clinical Center in 1961 and spent his entire scientific career there — making him one of only a handful of Nobel Laureates to conduct the entirety of their prize-winning research within a single institution, and the only NIH Nobelist to have worked primarily in clinical research.
Nobel laureate speaker Harvey Alter is best known for identifying “non-A, non-B hepatitis” — the mysterious form of liver disease that persisted in transfusion patients even after hepatitis A and B had been ruled out. Beginning in the 1970s, his landmark prospective studies demonstrated that this unknown agent was transmissible, viral in nature, and responsible for a large proportion of chronic liver disease globally. His meticulous work — including the creation of a carefully maintained repository of patient blood samples that became foundational to the field — provided the scientific bedrock upon which Michael Houghton later isolated the virus in 1989, and Charles Rice confirmed it as the sole causative agent. The trio shared the Nobel Prize in 2020 for a body of work that the Nobel Committee called “a landmark achievement in the ongoing battle against viral diseases.”
Alter’s contribution to public health extends far beyond the Nobel Prize itself. As principal investigator on sequential prospective studies of transfusion-associated hepatitis, he documented the decline of infection rates from 33% of transfusion recipients in the 1960s to near zero by 1997 — a transformation driven directly by the screening protocols his research made possible. He also co-discovered the Australia antigen as a young research fellow alongside Baruch Blumberg, contributing to the identification of hepatitis B, for which Blumberg received the 1976 Nobel Prize. Today, Alter continues as a Senior Scholar at the NIH Clinical Center’s Department of Transfusion Medicine, and in 2024 NIH honored his legacy with a dedicated exhibit: “Harvey Alter and the Discovery of Hepatitis C: Making Our Blood Supply Safe.” His honors include the Albert Lasker Clinical Medical Research Award, the Canada Gairdner International Award, the Distinguished Service Medal, and election to both the National Academy of Sciences and the National Academy of Medicine.
As a Nobel Prize speaker, Harvey Alter brings something genuinely rare to the stage: the lived experience of a half-century scientific quest, told with the clarity, intellectual honesty, and — by universal acclaim among colleagues — a dry wit that makes complex virology and medical history utterly compelling. His keynotes illuminate not just the science of hepatitis C, but the nature of great scientific inquiry itself: the patience required, the institutional support that enables it, and what it means to dedicate a career to a question whose answer saves millions of lives. For healthcare, pharmaceutical, and scientific audiences, there is no more authoritative or engaging voice on the history and future of blood safety and viral disease.
In this signature lecture, Alter traces the full arc of one of modern medicine's most consequential scientific investigations — from the baffling persistence of post-transfusion hepatitis in the 1970s, through the painstaking epidemiological studies that defined a new disease, to the Nobel Prize-winning discovery of the virus itself and the treatments that followed. More than a history of hepatitis C, this is a masterclass in what rigorous, patient-driven scientific inquiry looks like over a lifetime — and what it can ultimately achieve.
The near-elimination of transfusion-transmitted hepatitis C is one of the great underrecognized public health achievements of the 20th century. Alter presents the inside story: how prospective clinical studies shaped national blood policy, how scientific evidence was translated into regulatory action, and what the resulting decline from 33% infection rates to near zero tells us about the relationship between basic research, public health infrastructure, and the will to act on evidence. A compelling talk for healthcare executives, policymakers, and anyone working at the interface of science and health systems.
Few scientists have dedicated as much of a career to a single question as Harvey Alter — and fewer still have seen that question answered so definitively. In this reflective keynote, he explores what sustained scientific inquiry actually demands: the institutional conditions that enable it, the intellectual honesty required to follow data rather than assumptions, the role of mentorship and collaboration, and what kept him at the bench long after a lesser ambition would have been satisfied. A talk for scientists, researchers, academic leaders, and anyone who believes that the best ideas take time.
Despite the availability of treatments with over 95% cure rates, hepatitis C remains a major global health burden — with an estimated 50 million people still living with the infection and access to treatment deeply unequal across income levels and geographies. Alter examines where we are in the global elimination effort, what scientific and policy obstacles remain, and what the story of hepatitis C's discovery and treatment teaches us about the gap between what medicine can do and what it actually delivers at scale.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see “PRIVACY POLICY” on our website. |